Infectious Mononucleosis Panel

The Infectious Mononucleosis Panel is a blood test used to assess the antibody response to Epstein-Barr virus, or EBV, one of the most common causes of infectious mononucleosis. The panel includes EBV EA/VCA IgG, EBV EBNA IgG, and EBV VCA IgM. These markers are interpreted together because each antibody develops at a different stage of infection.

Testing may be considered when symptoms such as fever, sore throat, swollen lymph nodes, prolonged recovery after a viral illness, fatigue and low energy, or headaches, migraines and dizziness raise concern about infectious mononucleosis. These symptoms are not specific to EBV and may also occur with other infections or medical conditions, so laboratory results must be assessed together with the clinical picture.

What the panel measures

• EBV VCA IgM: IgM antibodies against the viral capsid antigen usually appear early in a primary EBV infection. They commonly disappear within approximately four to six weeks.
• EBV EA/VCA IgG: IgG antibodies against early and viral capsid antigens may be detected during the acute phase. VCA IgG generally remains detectable for life, while antibodies against early antigen often decrease during the following months but may persist in some people.
• EBV EBNA IgG: IgG antibodies against the EBV nuclear antigen usually do not appear during the early acute phase. They generally develop later, often two to four months after symptoms begin, and commonly remain detectable throughout life.

The EBNA result included in this panel is an IgG antibody result. EBNA is the antigen being tested, rather than a separate immunoglobulin class. This distinction is important when comparing EBNA with VCA IgM and EA/VCA IgG.

How the antibody pattern may be interpreted

A positive VCA IgM result together with a negative EBNA IgG result may support a primary or recent EBV infection. A positive IgG response together with positive EBNA IgG and negative VCA IgM is more consistent with an infection that occurred in the past. Positive EA-related IgG does not independently prove that current symptoms are caused by active EBV because these antibodies may remain detectable in some people after recovery.

No individual marker should be interpreted alone. A high IgG value does not necessarily mean that an infection is recent, and a positive EBNA IgG result commonly reflects previous exposure. Results that do not follow a typical pattern may require review of symptom timing, previous laboratory reports, additional testing, or a repeat sample.

Why the timing of the blood sample matters

EBV antibody patterns change during the course of an infection. VCA IgM may appear early, VCA IgG develops during the acute phase, and EBNA IgG usually appears later. Testing very soon after symptoms begin can therefore produce a negative or incomplete pattern even when EBV infection is still clinically suspected.

When an early result is negative or equivocal but symptoms remain compatible with infectious mononucleosis, repeat serology after approximately 10 to 14 days may be considered. The appropriate timing depends on when symptoms started, which antibodies were detected, and whether another cause of the illness is being investigated.

How the testing process works

Step 1: Record the timing and symptoms

Before testing, note when the illness began and whether there has been fever, sore throat, swollen lymph nodes, marked tiredness, headache, reduced appetite, abdominal discomfort, or a prolonged recovery. Previous EBV results and other recent infection tests can help with comparison.

Step 2: Blood sample collection

No special preparation is required. A blood sample is collected during a short outpatient appointment and sent for serological analysis.

Step 3: Laboratory analysis

The sample is analyzed for EBV EA/VCA IgG, EBV EBNA IgG, and EBV VCA IgM. Each result is reported according to the laboratory method and applicable reference criteria.

Step 4: Receiving and interpreting the report

The laboratory report is expected within 5 to 7 business days. Interpretation should consider the complete antibody pattern, the number of days or weeks since symptoms began, age, immune status, clinical findings, and any previous EBV results.

Important limitations

The panel can support assessment of recent or past EBV infection, but it does not determine by itself whether every current symptom is caused by EBV. Similar symptoms may occur with cytomegalovirus, other viral or bacterial infections, hematological conditions, or noninfectious causes.

Medical assessment should not be delayed in the presence of severe abdominal pain, breathing or swallowing difficulty, marked dehydration, confusion, jaundice, fainting, rapidly worsening symptoms, or concern about an enlarged spleen. Contact sports and activities with a risk of abdominal impact may need to be avoided when infectious mononucleosis or spleen enlargement is suspected, based on medical advice.

What to prepare for an inquiry

When sending an inquiry through ZagrebMed, include the date symptoms began, the main symptoms, any previous EBV or infection results, current medications, known medical conditions, and whether a medical examination has already been recommended. This information can help determine whether the panel is an appropriate first step or whether an examination or additional testing should also be arranged.